CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 35 enrolled
Drug / intervention
Nivolumab +4 moredrug
Likely dose
Nivolumab 240mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02754726
NCT02754726Phase 2Completed
CompareCT.gov

A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

HonorHealth Research Institute·interventional·Posted Apr 28, 2016·Updated Aug 27, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Albumin-bound paclitaxel, and 3 other interventions for Untreated Metastatic Pancreatic Ductal Adenocarcinoma. Completed, enrolled 35 participants across 1 site.

Detailed Summary

The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUntreated Metastatic Pancreatic Ductal Adenocarcinoma
CountriesUnited States
CollaboratorsTranslational Genomics Research Institute, Bristol-Myers Squibb, Lustgarten Foundation

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 28, 2016
Enrollment StartApr 1, 2016
Primary CompletionApr 11, 2023
Study CompletionMar 22, 2024
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 10.2 years ago

Interventions

Nivolumabdrug

Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle

Albumin-bound paclitaxeldrug

125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Paricalcitoldrug

25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle

Cisplatindrug

25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle

Gemcitabinedrug

1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle